跳至主要内容

Medicilon’s Drug ADME/PK Assays Services

 Medicilon’s pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and etc. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai government.

adme services

Available PK Studies Include:

  • Method development and validation (GLP,Non-GLP)
  • Bioanalysis
  • Pharmacokinetics (Tumor bearing rodents, Bioavailability,
  • Crossover studies,  Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB  penetration )
  • Stability in vehicles and plasma
  • Drug interaction studies
  • In vitro metabolic stability
  • Prediction and identification of major metabolites
  • Toxicokinetics analysis
  • Distribution studies

In Vivo ADME Services

Medicilon offers a suite of in vivo ADME services and features a team with over 12 years of experience. We are equipped to conduct in-life studies in rat ,pig , mouse and dog. We provide comprehensive radiolabel ADME study support across non-clinical species.
Available studies include:

  • Excretion Studies
  • Tissue Distribution
  • Plasma Protein Binding Studies
  • Others……

Bioanalysis:

  • Advanced bioanalytical method development
  • Advanced bioanalytical method validation
  • Pharmacokinetics
  • Others……

In Vitro ADME Services

With extensive knowledge of in vitro ADME and pharmacokinetics gained through working within drug discovery environments at both pharmaceutical and biotech companies, our ADME experts offer a consultative approach ensuring that the right experiments are performed at the right time.

ADME Assays SERVICES has been created with the objective to give support on pharmacokinetics and metabolism studies to small and mid-size pharmaceutical and biotech companies involved in research and development of new drugs or new formulations.

• Absorption ‐ route of drug delivery
• Distribution ‐ where does the drug go, where does it need to go and what
are the implications
• Metabolism Metabolism ‐ this will occur and could impact several several variables variables
• Excretion – how is the drug eliminated

• Pharmacokinetics is concerned with the variation in drug concentration with time as a result of absorption, metabolism, distribution and excretion
– Drug dose, route of administration, administration, rate and extent of absorption, absorption, distribution distribution rate (particularly to site of action) and rate of elimination
– Pharmacokinetics may be simply defined as what the body does to the drug
– Pharmacodynamics defined as what the drug does to the body

These pharmacokinetic processes, often referred to as ADME, determine the drug concentration in the body when medicines are prescribed.

Contact US

Email : marketing@medicilon.com
Tel : +86 021 58591500

Tips : Above is part of drug adme assays , adme study services and pharmacokinetics adme Services. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

Related Articles:

Preclinical ADME Studies

Factors Affecting Pharmacokinetics of Drugs

High-throughput ADME research in the new drug discovery phase

ADME Pharmacokinetics Studies

High Throughput ADME Study of New Drug Discovery

Drug absorption, distribution, metabolism and excretion (pharmacokinetics)

评论

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

  On July 20, 2020, DAC Biotech’s new   ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed   preclinical pharmacokinetic  and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...